Sector News

Johnson & Johnson to buy Auris Health for $3.4 billion

February 13, 2019
Life sciences

Johnson & Johnson said Wednesday it would buy robotic surgery firm Auris Health for $3.4 billion in cash.

The purchase gives J&J, one of the world’s largest maker of health products, an entry into robotics and builds on the company’s partnership with Alphabet’s Verily.

“In this new era of health care, we’re aiming to simplify surgery, drive efficiency, reduce complications and improve outcomes for patients, ultimately making surgery safer,” said Ashley McEvoy, company group chair of consumer medical devices, in a press release. “Collectively, these technologies, together with our market-leading medical implants and solutions, create the foundation of a comprehensive digital ecosystem to help support the surgeon and patient before, during and after surgery.”

The company is divided in three main business units: pharmaceuticals, medical devices and consumer products. J&J’s medical device business has been lagging, with sales falling 4 percent to $6.67 billion in the fourth quarter of 2018. The health-care company has vowed to improve performance through acquisitions and divestitures.

Last year, J&J divested its LifeScan blood glucose monitor business after exiting the insulin pump market.

Bloomberg reported last month that J&J was pursing an acquisition of Auris Health, a privately held developer of robotic technologies. J&J said Wednesday it’s creating a “connected digital ecosystem” that uses data and robotic technology to guide surgeon through procedures and improve patient treatment.

The surgical instruments business is expected to reach more than $12 billion by 2025, with the biggest players in the space including J&J, Medtronic, and Intuitive Surgical.

J&J CEO Alex Gorsky noted in a fourth-quarter earnings call last month that investors would see “continued news about our robotics platform over the course of 2020 and beyond.”

“What we want to make sure is that we get out in a timely manner,” he said, “but that we’re also out in a manner that ensures we’re competitive and ensures, ultimately, that we’re making an even bigger difference in this area as we go forward.”

The transaction is expected to close by the end of the second quarter of 2019.

J&J’s stock was slightly higher in premarket trading Wednesday. The stock is up nearly 4 percent since the beginning of this year. Shares are more than 2 percent higher over the last 12 months.

By Berkeley Lovelace Jr.

Source: CNBC

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.